Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Restructuring Costs (2022 - 2024)

Historic Restructuring Costs for InMed Pharmaceuticals (INM) over the last 3 years, with Q2 2024 value amounting to $104969.0.

  • InMed Pharmaceuticals' Restructuring Costs rose 22935.66% to $104969.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $43726.0, marking a year-over-year change of. This contributed to the annual value of $162200.0 for FY2024, which is 18754.79% up from last year.
  • As of Q2 2024, InMed Pharmaceuticals' Restructuring Costs stood at $104969.0, which was up 22935.66% from $9768.0 recorded in Q1 2024.
  • InMed Pharmaceuticals' 5-year Restructuring Costs high stood at $104969.0 for Q2 2024, and its period low was -$81147.0 during Q2 2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Restructuring Costs value was $19289.0 (recorded in 2023), while the average stood at $19368.3.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Restructuring Costs tumbled by 7698.56% in 2023, and later surged by 22935.66% in 2024.
  • Over the past 3 years, InMed Pharmaceuticals' Restructuring Costs (Quarter) stood at $44042.0 in 2022, then crashed by 76.99% to $10136.0 in 2023, then skyrocketed by 935.61% to $104969.0 in 2024.
  • Its Restructuring Costs was $104969.0 in Q2 2024, compared to $9768.0 in Q1 2024 and $10136.0 in Q4 2023.